Optimization of a series of potent and selective ketone histone deacetylase inhibitors
- 15 October 2008
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (20) , 5528-5532
- https://doi.org/10.1016/j.bmcl.2008.09.003
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivoMolecular Cancer Therapeutics, 2008
- Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)Bioorganic & Medicinal Chemistry Letters, 2008
- Novel Aminophenyl Benzamide-Type Histone Deacetylase Inhibitors with Enhanced Potency and SelectivityJournal of Medicinal Chemistry, 2007
- Histone deacetylases and cancerOncogene, 2007
- Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8–substrate complexEMBO Reports, 2007
- Histone deacetylase inhibitors in cancer therapyExpert Opinion on Investigational Drugs, 2007
- VorinostatNature Reviews Drug Discovery, 2007
- The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug ResistanceCancer Research, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Histone-deacetylase inhibitors: novel drugs for the treatment of cancerNature Reviews Drug Discovery, 2002